Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
목요일, 8월 20

Hims & Hers Health Inc

HIMSNYSE
Trade with Public
Trade with Public
$31.09
3.7013.51%
가까이에: Aug 19, 5:00 PM EST
$30.80
-0.29-0.93%
시간외: 7:59 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Hims & Hers Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Hims & Hers Health (HIMS).

Price Target Range — 10 Quarters

Analyst Consensus — 14 Analysts

4Buy
10Hold
Consensus RatingHold# Analysts14Avg. Consensus PT$31Upside to Avg. PT+0.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 11, 2026CitigroupDaniel GrosslightPT CutNeutral$35→$33
Aug 11, 2026Deutsche BankGeorge HillPT RaiseHold$25→$26
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Hims & Hers Health, Lowers Price Target to $33

Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $35 to $33.
Benzinga Newsdesk

PRO
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26

Deutsche Bank analyst George Hill maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $26.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price target from $30 to $32.
Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Hims & Hers Health, Raises Price Target to $30

TD Cowen analyst Jonna Kim maintains Hims & Hers Health (NYSE:HIMS) with a Hold and raises the price target from $25 to $30.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Hims & Hers Health, Raises Price Target to $28

Morgan Stanley analyst Craig Hettenbach maintains Hims & Hers Health (NYSE:HIMS) with a Equal-Weight and raises the price target from $21 to $28.
Benzinga Newsdesk

Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst

HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
Priya Nigam

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved